Aim: To investigate the impact of moderate-intensity exercise and pre-exercise blood glucose concentrations (BG) on the demand of orally administered carbohydrates (CHO) to maintain euglycemia (> 70 - 180 mg/dL) during endurance exercise sessions performed over 5 consecutive days on either a regular (100%) or reduced dose (75%) of insulin degludec (IDeg) in people with type 1 diabetes (T1D).

Methods: Nine participants with T1D (four women, mean age 32.1 ± 9.0 years, BMI 25.5 ± 3.9 kg/m2, glycated hemoglobin 55 ± 7 mmol/mol [7.2 ± 0.6%]) on IDeg were randomized to cycle for 55 minutes at moderate intensity (63 ± 7% VO2max) for 5 consecutive days on either 100% or 75% of their regular IDeg dose. The exercise accumulating effect was analysed via one-way-ANOVA for repeated measures (day x administered CHO). The influence of pre-exercise BG was analysed by one-way ANOVA or Kruskal-Wallis stratified for BG quartiles and Spearman correlation. The effect of IDeg dose (100% vs. 75%) on given CHO was calculated via Wilcoxon or student's t-test (p<0.05).

Results: No exercise accumulating effect was found (p>0.05) but CHO intake was significantly related to pre-exercise BG (r=-0.45; p<0.0001).

Conclusion: Pre-exercise BG had a significant influence on the demand of orally administered CHO to maintain euglycemia during exercise over 5 consecutive days.

graphic
View largeDownload slide
Disclosure

M.L. Eckstein: Research Support; Self; Novo Nordisk A/S. O. Moser: Research Support; Self; Abbott, Dexcom, Inc., Novo Nordisk A/S. A. Mueller: None. P. Birnbaumer: None. F. Aberer: None. G. Koehler: Advisory Panel; Self; Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk A/S. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Lilly Diabetes, Novo Nordisk A/S, Sanofi-Aventis Deutschland GmbH. C. Sourij: None. H. Kojzar: None. P.N. Pferschy: None. P. Dietz: None. R.M. Bracken: None. P. Hofmann: None. H. Sourij: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Novo Nordisk A/S, Sanofi-Aventis. Speaker’s Bureau; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis.

Funding

Novo Nordisk Pharma GmbH

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.